CINECA IRIS Institutional Research Information System

Sfoglia per Autore  

Opzioni
Mostrati risultati da 21 a 40 di 157
Titolo Data di pubblicazione Autore(i) File
Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines 2006 Fernando A; Glaysher S; Conroy M; Pekalski M; Smith J; Knight LA; Di Nicolantonio F; Cree IA
Anti-EGFR Antibody Therapy Based on an Increased Copy Number of the EGFR Gene in Tumor Tissues 2006 Salvatore Siena; Mauro Moroni; Giovanna Marrapese; Andrea Sartore-Bianchi; Silvio Veronese; Marcello Gambacorta; Silvia Benvenuti; Federica Di Nicolantonio; Alberto Bardelli
The effect of imatinib mesylate (Glivec) on human tumor-derived cells 2006 Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
Kinase mutations in cancer: chinks in the enemy's armour? 2006 F. DI NICOLANTONIO; A. BARDELLI
Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus 2006 Bhandari P; Bateman AC; Mehta RL; Stacey BSF; Johnson P; Cree IA; Di Nicolantonio F; Patel P
Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti– Epidermal Growth Factor Receptor Antibody Therapies 2007 SILVIA BENVENUTI; ANDREA SARTORE-BIANCHI; FEDERICA DI NICOLANTONIO; CARLO ZANON; MAURO MORONI; SILVIO VERONESE; SALVATORE SIENA; ALBERTO BARDELLI
Knock-in of oncogenic mutations in human somatic cells as a tool to identify genoselective compounds 2007 Federica Di Nicolantonio; Sabrina Arena; Margherita Gallicchio; Miriam Martini; Davide Zecchin; Simona Flonta; Giulia Stella; Giovanni Appendino; Roberto Fantozzi; Enzo Medico; Alberto Bardelli
Costruzione di linee cellulari isogeniche per mutazioni associate al cancro e loro applicazione per approcci di farmacogenomica 2008 Bardelli A; Di Nicolantonio F; Arena S
ISOGENIC HUMAN CELL LINES COMPRISING MUTATED CANCER ALLELES AND PROCESS USING THE CELL LINES 2008 BARDELLI A; DI NICOLANTONIO F; ARENA S
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses 2008 Di Nicolantonio F ; Arena S; Gallicchio M; Zecchin D; Martini M; Flonta SE; Stella GM; Lamba S; Cancelliere C; Russo M; Geuna M; Appendino G; Fantozzi R; Medico E; Bardelli A
BRAF V600E confers resistance to cetuximab or panitumumab metastatic colorectal cancer 2008 Di Nicolantonio F; Martini M; Molinari F; Bianchi AS; Arena S; Saletti P; Mazzucchelli L; Frattini M; Siena S; Bardelli A
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer 2008 Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies 2009 Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-RaSG13D 2009 Palmioli A; Sacco E; Airoldi C; Di Nicolantonio F; D'Urzo A; Shirasawa S; Sasazuki T; Di Domizio A; De Gioia L; Martegani E; Bardelli A; Peri F; Vanoni M
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer 2009 Siena S; Sartore-Bianchi A; Di Nicolantonio F; Balfour J; Bardelli A
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer 2009 Sartore-Bianchi A*; Di Nicolantonio F*; Nichelatti M; Molinari F; De Dosso S; Saletti P; Martini M; Cipani T; Marrapese G; Mazzucchelli L; Lamba S; Veronese S; Frattini M; Bardelli A;^ Siena S^ (*shared first authorship; ^shared last authorship)
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. 2010 Di Nicolantonio F; Arena S; Tabernero J; Grosso S; Molinari F; Macarulla T; Russo M; Cancelliere C; Zecchin D; Mazzucchelli L; Sasazuki T; Shirasawa S; Geuna M; Frattini M; Baselga J; Gallicchio M; Biffo S; Bardelli A
Isogenic mutant human cells: a new tool for personalized cancer medicine 2010 Di Nicolantonio F; Arena S; Gallicchio M; Bardelli A
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer 2010 Sartore-Bianchi A; Bencardino K; Cassingena A; Venturini F; Funaioli C; Cipani T; Amatu A; Pietrogiovanna L; Schiavo R; Di Nicolantonio F; Artale S; Bardelli A; Siena S
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer 2010 Sartore-Bianchi A; Bencardino K; Di Nicolantonio F; Pozzi F; Funaioli C; Gambi V; Arena S; Martini M; Lamba S; Cassingena A; Schiavo R; Bardelli A; Siena S
Mostrati risultati da 21 a 40 di 157
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile